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We describe a pilot study that attempted to infect
human volunteers with Cyclospora cayetanensis. Seven
healthy volunteers ingested an inoculum of Cyclospora
oocysts (approximately 200–49,000 oocysts). The volun-
teers did not experience symptoms of gastroenteritis, and
no oocysts were detected in any stool samples during the
16 weeks volunteers were monitored.
C
yclospora cayetanensis is a protozoan parasite that
may cause gastroenteritis with prolonged, intermittent
diarrhea in humans. Characterization and magnitudes of
risk factors associated with food and water consumption
are unclear because the dose-response relationship and
other host-parasite factors for infection with Cyclospora
are unknown. To characterize infectivity, we performed a
study in which inocula of Cyclospora oocysts were admin-
istered to human volunteers.
The Study
Stool samples containing high concentrations of
Cyclospora oocysts and serum specimens were collected
from persons with cyclosporiasis in Haiti and the United
States. Informed consent was obtained from persons pro-
viding the specimens. The Centers for Disease Control and
Prevention (CDC) institutional review board (IRB)
reviewed specimen collection, informed consent, and
patient counseling procedures. Stool specimens were
homogenized with water and sieved through cheesecloth.
Since Cyclospora oocysts must form sporocysts outside
the human host before becoming infectious, the filtrate
was resuspended in potassium dichromate (2.5%) and
shaken for about 3 weeks at room temperature to induce
sporulation. After sporulation (67%–94% of oocysts
sporulated), samples were stored at room temperature until
further processing (2–3 months).  Suspensions with the
highest oocyst counts were purified and concentrated by
sucrose and cesium chloride gradients (1). See the Table
for additional inoculum treatment conditions. 
Each candidate inoculum was tested for Salmonella
spp., Shigella spp.,  Campylobacter spp., Yersinia spp.,
Mycobacterium spp., Escherichia coli O157:H7,
enteroviruses,  Hepatitis A virus (HAV),  Herpesvirus,
Cytomegalovirus,  Coronavirus,  Astrovirus,  Rotavirus,
Norovirus,  Adenovirus, HIV, Clostridium difficile toxin,
enterotoxin, and intestinal parasites (data not shown).
Serum specimens from the donors of Cyclospora-positive
stools were tested for serum markers of HIV, HAV,
Hepatitis B virus, and Taenia solium. If serum from a
Cyclospora-positive stool donor tested positive for any of
the above, oocysts from that person were not used.
Candidate inocula in which none of these pathogens or
toxins were found were used in the human challenge study.
This safety-testing protocol was reviewed and approved by
both the University of North Carolina School of Medicine
IRB and the CDC IRB. Cell culture infectivity assays and
animal models were not available to determine the infec-
tivity or viability of the oocysts. Attempts were made to
assess the viability of the inoculum by observing sporo-
zoite motility after excystation of the oocysts by different
methods. However, these methods did not yield a sufficient
number of motile sporozoites to measure viability.
The study was conducted at the General Clinical
Research Center at the University of North Carolina
Hospital, Chapel Hill, NC. Inclusion and exclusion criteria
determined whether a person was eligible to participate in
the study. Healthy volunteers were recruited from the
University of North Carolina (UNC), Chapel Hill, NC, and
the surrounding community. Before enrollment, each can-
didate received a medical evaluation, and preinoculation
serum specimens were collected and archived. The seven
study participants comprised four women and three men;
three were white, and four were African American. The
median age was 26.
After ingesting the inoculum, volunteers were asked to
collect all stool specimens for 4 weeks and one specimen a
week at weeks 5, 6, 8, and 16. They were also asked to
keep a daily record of physical symptoms and the time of
each stool passage. In addition, volunteers provided blood
and saliva specimens weekly for 6 weeks and at weeks 8
and 16 postdosing. Study outcome measures were a) shed-
ding Cyclospora oocysts in stool; b) frequency, weight,
color, and consistency of stool; and c) clinical symptoms
of gastroenteritis: diarrhea (>3 stools in 24 hours), nausea,
vomiting, abdominal pain, myalgia, headache, fever,
chills, or fatigue. 
Stools were examined to detect oocysts at UNC Chapel
Hill. All stool specimens were concentrated by using the
formalin-ethyl acetate concentration procedure routinely
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addition, to increase the sensitivity of detection, all stools
from the first 2 weeks postdosing were concentrated by a
sucrose floatation procedure (1). Aliquots of the concentrat-
ed sample from each procedure were examined microscop-
ically by using a wet mount preparation (2), and 87% of
these concentrates were confirmed by a second laboratory
at CDC. Criteria to identify Cyclospora oocysts were based
on size, morphologic characteristics, and ability of the
oocysts to autofluoresce under epifluorescence (3). 
Inoculum treatment and challenge conditions of this
study are described in the Table. Numbers of stools exam-
ined per volunteer ranged from 19 to 40; no oocysts were
detected in any of the stool samples. Volunteer 1 experi-
enced a brief episode of abdominal cramps on day 7 post-
dosing. This volunteer attributed the symptom to possible
dehydration due to strenuous activity performed in the heat
that day. Volunteer 5 produced four loose stools on day 10
postdosing but reported feeling well. This volunteer also
had a mildly elevated leukocyte count (15.8 x 109/L; nor-
mal range 4.5–11.0 x 109/L) on day 13 postdosing.
However, this volunteer had a mildly elevated baseline
leukocyte count (13.8 x 109/L) 14 days before dosing.
Overall, no conclusive evidence based on clinical or para-
sitologic diagnostic procedures showed that any volunteers
became infected.
Conclusions
Cyclosporiasis continues to be a difficult emerging
infectious disease to understand. Our results are consistent
with other researchers’inability to establish C. cayetanen-
sis infection in a wide variety of animal models (4). Given
these results, questions relating to host susceptibility and
risk factors for infection with Cyclospora, the biology of
C. cayetanensis, survival conditions for C. cayetanensis in
vitro and in vivo, and factors that allow Cyclospora to
become infectious in the environment need further study. 
Host susceptibility and risk factors for infection are
always a consideration when evaluating host response to
pathogen exposure. Epidemiologic data suggest that
immunity may develop to C. cayetanensis in areas where
cyclosporiasis is endemic and that the disease is more
severe in naïve populations (5). Persons affected in food-
borne outbreaks of cyclosporiasis in North America were
mostly adults who experienced prolonged symptomatic
gastroenteritis, and median food-specific attack rates were
high (6,7). In this study, only healthy adult volunteers
(22–53 years of age) were recruited from areas in which
cyclosporiasis is not known to be endemic. Therefore,
although the number of volunteers in this study was small
(N = 7), epidemiologic data suggest that host susceptibili-
ty factors did not substantially contribute to inability of the
inocula to cause infection in the volunteers at the doses
administered. 
Virulence and characteristics of Cyclospora necessary
to infect human hosts are unknown. Nucleotide sequence
variability in the first internal transcribed spacer regions
within C. cayetanensis from different geographic origins
has been observed and suggests the existence of multiple
strains (8,9). In addition, data from Cryptosporidium
human volunteer studies demonstrated that the 50% infec-
tious dose (ID50) differed (from 9 to 1,042 oocysts),
depending on the isolate used in the study (10). For these
reasons, we attempted to vary the inocula by selecting
oocysts from persons in different geographic regions
(Haiti, Missouri, and Georgia) and increasing the numbers
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Table. Inoculum treament and challenge conditions from the Cyclospora human challenge study  
Volunteer 
Oocysts  
source (no.)
b 
Oocysts ingested, mean ± 
SD (% sporulated)  Inoculum
 disinfection
c,d 
Storage medium 
until dosing 
Total storage 
(mo)
e 
Inoculum ingestion 
medium and conditions 
1  Haiti (3)  647 ± 183 (82)  Bleach and thiosulfate 
(pre-storage) 
Sterile water  6+  Sterile water, then  
light lunch 
2  Haiti (3)  203 ± 22 (69)  Bleach and thiosulfate 
(pre-storage) 
Sterile water  7+  Sterile water, then  
light lunch 
3  Haiti (1)  884 ± 22 (96)  Bleach and thiosulfate 
(pre-storage) 
Sterile water  10  Sterile water, then 
 light lunch 
4  MO, USA (1)  4,851 ± 545 (71)  Bleach only; wash on 
dosing day 
Sterile PBS  6+  Sterile water, with a 
chicken salad meal 
5  MO, USA (1)  1,815 ± 249 (67)  Thiosulfate only; wash 
on dosing day 
Sterile PBS  7  Sterile water, with a 
chicken salad meal 
6  MO, USA (1)  4,916 ± 1,153 (67)  Bleach and thiosulfate 
(pre-storage) 
Sterile PBS  7+  Sterile water, with a 
chicken salad meal 
7  GA, USA (1)  48,884  ± 15,345 (94)  Bleach and thiosulfate 3 
days predosing 
2.5% dichromate  5  Raspberries, then  
light lunch 
aMO, Missouri; GA, Georgia; PBS, phosphate-buffered saline.
 
bno., number of stool donors 
cHousehold bleach (5.25% sodium hypochlorite) was used for disinfection, and sodium thiosulfate (0.01%–0.1%) was used to inactivate residual bleach in the inocula. 
dFor safety testing laboratory details, contact corresponding author. 
eTime in storage from stool collection until volunteer dosing date, includes time oocysts were exposed to potassium dichromate in stool until sporulation plus the time the 
extracted oocysts were in storage media. 
 of oocysts ingested by volunteers (from <1,000 oocysts to
approximately 49,000) during the course of this study.
Thus, differences in virulence characteristics of C. cayeta-
nensis isolates appear not to have been a major factor in
failing to establish infection. 
All oocysts in stool samples in this study were stored in
potassium dichromate (2.5%), and most of the final inocu-
lum preparations were disinfected with bleach (5.25%).
Cryptosporidium parvum has been stored in 2.5% potassi-
um dichromate (for <6 weeks to >12 weeks) and remained
infectious in human volunteers, cell culture, and animals
(11,12). Also, baboons inoculated with oocysts never
exposed to potassium dichromate were not infected with
Cyclospora (M. Eberhard, unpub. data). Other parasites of
genera related to Cyclospora (Cryptosporidium, Eimeria
spp., Toxoplasma gondii, sporocysts of Sarcocystis spp.)
have been shown to resist high levels of bleach (13–15).
However, the effects of potassium dichromate and bleach
on the Cyclospora oocysts used in this study are unknown,
since methods to evaluate infectivity and viability were not
available.  
Naturally occurring Cyclospora oocysts may survive for
extended periods in the environment, given the marked sea-
sonality of infection in areas where the disease is endemic
(6). However, many questions remain about the triggers
and conditions necessary for Cyclospora oocysts to survive
and become infectious in the environment. Given the
results of this study, conditions necessary for Cyclospora to
become infectious were probably not achieved in preparing
and storing the oocysts. Future studies are necessary to
examine individual and combined effects of temperature,
humidity, storage media, and disinfection on the survival,
viability, and infectivity of stored Cyclospora oocysts.
These studies would help determine optimal conditions to
stimulate sporulation and maintain infectivity of oocysts in
vitro over time. However, such studies will not be possible
until suitable cell culture systems or animal host models for
cyclosporiasis are developed.
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